Connection

Co-Authors

This is a "connection" page, showing publications co-authored by JUAN LOPEZ-MATTEI and KAVEH KARIMZAD.
Connection Strength

0.576
  1. QT Prolongation in Cancer Patients. Front Cardiovasc Med. 2021; 8:613625.
    View in: PubMed
    Score: 0.192
  2. Trigger related outcomes of takotsubo syndrome in a cancer population. Front Cardiovasc Med. 2022; 9:1019284.
    View in: PubMed
    Score: 0.054
  3. Reclassification of Treatment Strategy with Fractional Flow Reserve in Cancer Patients with Coronary Artery Disease. Medicina (Kaunas). 2022 Jul 01; 58(7).
    View in: PubMed
    Score: 0.053
  4. Cardiac Interventional Procedures in Cardio-Oncology Patients. Cardiol Clin. 2019 Nov; 37(4):469-486.
    View in: PubMed
    Score: 0.044
  5. Fulminant Vascular and Cardiac Toxicity Associated with Tyrosine Kinase Inhibitor Sorafenib. Cardiovasc Toxicol. 2019 08; 19(4):382-387.
    View in: PubMed
    Score: 0.043
  6. Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. Am J Cardiol. 2019 04 15; 123(8):1351-1357.
    View in: PubMed
    Score: 0.042
  7. Interventional Cardio-Oncology: Adding a New Dimension to the Cardio-Oncology Field. Front Cardiovasc Med. 2018; 5:48.
    View in: PubMed
    Score: 0.040
  8. Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. Can J Cardiol. 2017 10; 33(10):1335.e13-1335.e15.
    View in: PubMed
    Score: 0.037
  9. Ischemic Heart Disease: Special Considerations in Cardio-Oncology. Curr Treat Options Cardiovasc Med. 2017 May; 19(5):37.
    View in: PubMed
    Score: 0.037
  10. Takotsubo Stress Cardiomyopathy: "Good News" in Cancer Patients? J Am Coll Cardiol. 2016 09 06; 68(10):1143-4.
    View in: PubMed
    Score: 0.035
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.